Publication | Closed Access

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old

Hematological MalignancyPhase Ii TrialMedicineMixed-phenotype Acute LeukemiaHematologyMyeloid NeoplasiaArsenic TrioxideLeast 65OncologyRadiation OncologyHealth Sciences